Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 1, 2009, Pages 33-49

  Borrelli, Francesca ^a   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

acylethanolamides; anandamide; appetite; feeding behaviour; intestine; oleoylethanolamide; palmitoylethanolamide

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYLETHANOLAMIDE; ADENOVIRUS VECTOR; ANANDAMIDE; ANOREXIGENIC AGENT; ARACHIDONOYLSEROTONIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 55; LIPID; LORGLUMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; OLEIC ACID; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RIMONABANT; STEAROYLETHANOLAMIDE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

BIOLOGICAL ACTIVITY; CELL MEMBRANE; CELL PROLIFERATION; COLITIS; COLON CANCER; DIARRHEA; DIETARY INTAKE; ENERGY BALANCE; ENTERITIS; ENTEROPATHY; FEEDING DISORDER; FOOD DEPRIVATION; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; INTESTINE CELL; INTESTINE MOTILITY; INTESTINE SECRETION; LIPID DEGRADATION; LIPID TRANSPORT; LIPOGENESIS; MODULATION; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; STOMACH ACID SECRETION; STOMACH PROTECTION; VISCERAL PAIN;

AMIDES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACIDS; CACO-2 CELLS; DIETARY FATS; EATING; ENERGY METABOLISM; ETHANOLAMINE; FEEDING BEHAVIOR; GASTRIC ACID; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; INTRA-ABDOMINAL FAT; OLEIC ACIDS; PALMITIC ACIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYUNSATURATED ALKAMIDES; TRPV CATION CHANNELS;

EID: 61649124735     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.003     Document Type: Review

References (103)

1. Lambert D.M., and Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Current Medicinal Chemistry 6 (1999) 757-773
2. Lambert D.M., and Muccioli G.G. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Current Opinion in Clinical Nutrition and Metabolic Care 10 (2007) 735-744
3. Petrosino S & Di Marzo V. Anandamide and other acylethanolamides. In Lajtha A (ed.). Neural lipids. Handbook of neurochemistry and molecular neurobiology, vol. 8, Heidelberg: Springer, in press.
4. Schuel H., Burkman L.J., Lippes J., et al. N-Acylethanolamines in human reproductive fluids. Chemistry and Physics of Lipids 121 (2002) 211-227
5. LoVerme J., La Rana G., Russo R., et al. The search for the palmitoylethanolamide receptor. Life Sciences 77 (2005) 1685-1698
6. Capasso R., Matias I., Lutz B., et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129 (2005) 941-951
7. Matias I., Gonthier M.P., Petrosino S., et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. British Journal of Pharmacology 152 (2007) 676-690
8. Izzo A.A., and Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57 (2008) 1140-1155
9. Di Marzo V., and Izzo A.A. Endocannabinoid overactivity and intestinal inflammation. Gut 55 (2006) 1373-1376
10. Wright K.L., Duncan M., and Sharkey K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British Journal of Pharmacology 153 (2008) 263-270
11. Storr M.A., and Sharkey K.A. The endocannabinoid system and gut-brain signalling. Current Opinion in Pharmacology 7 (2007) 575-582
12. Wright K., Rooney N., Feeney M., et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129 (2005) 437-543
13. Hinds N.M., Ullrich K., and Smid S.D. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. British Journal of Pharmacology 148 (2006) 191-199
14. Guagnini F., Valenti M., Mukenge S., et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55 (2006) 946-953
15. McPartland J.M., Glass M., and Pertwee R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. British Journal of Pharmacology 152 (2007) 583-593
16. Geppetti P., and Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. British Journal of Pharmacology 141 (2004) 1313-1320
17. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. European Journal of Pharmacology 500 (2004) 231-241
18. Starowicz K., Nigam S., and Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics 114 (2007) 13-33
19. Ross R.A. Anandamide and vanilloid TRPV1 receptors. British Journal of Pharmacology 140 (2003) 790-801
20. Mang C.F., Erbelding D., and Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. British Journal of Pharmacology 134 (2001) 161-167
21. McVey D.C., Schmid P.C., Schmid H.H., et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). The Journal of Pharmacology and Experimental Therapeutics 304 (2003) 713-722
22. Ahern G.P. Activation of TRPV1 by the satiety factor oleoylethanolamide. The Journal of Biological Chemistry 278 (2003) 30429-30434
23. Wang X., Miyares R.L., and Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. The Journal of Physiology 564 (2005) 541-547
24. Brown A.J. Novel cannabinoid receptors. British Journal of Pharmacology 152 (2007) 567-575
25. Overton H.A., Fyfe M.C., and Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. British Journal of Pharmacology 153 Suppl. 1 (2008) S76-S81
26. Baker D., Pryce G., Davies W.L., et al. In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences 27 (2006) 1-4
27. Ryberg E., Larsson N., Sjögren S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 152 (2007) 1092-1101
28. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. British Journal of Pharmacology 152 (2007) 576-582
29. Mansén A., Guardiola-Diaz H., Rafter J., et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochemical and Biophysical Research Communications 222 (1996) 844-851
30. Yamazaki K., Shimizu M., Okuno M., et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56 (2007) 1557-1563
31. Linard C., Grémy O., and Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. The Journal of Pharmacology and Experimental Therapeutics 324 (2008) 911-920
32. Valasek M.A., Clarke S.L., and Repa J.J. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Journal of Lipid Research 48 (2007) 2725-2735
33. Sun Y., Alexander S.P., Garle M.J., et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. British Journal of Pharmacology 152 (2007) 734-743
34. Aviello G., Matias I., Capasso R., et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. Journal of Molecular Medicine 86 (2008) 413-422
35. Di Marzo V., Capasso R., Matias I., et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. British Journal of Pharmacology 153 (2008) 1272-1280
36. Fu J., Astarita G., Gaetani S., et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. The Journal of Biological Chemistry 282 (2007) 1518-1528
37. Sun Y.X., Tsuboi K., Okamoto Y., et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. The Biochemical Journal 380 (2004) 749-756
38. Izzo A.A., Capasso F., Costagliola A., et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125 (2003) 765-774
39. D'Argenio G., Valenti M., Scaglione G., et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. The FASEB Journal 20 (2006) 568-570
40. Giang D.K., and Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 2238-2242
41. Izzo A.A., Fezza F., Capasso R., et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. British Journal of Pharmacology 134 (2001) 563-570
42. Massa F., Marsicano G., Hermann H., et al. The endogenous cannabinoid system protects against colonic inflammation. The Journal of Clinical Investigation 113 (2004) 1202-1209
43. Fegley D., Gaetani S., Duranti A., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. The Journal of Pharmacology and Experimental Therapeutics 313 (2005) 352-358
44. Ueda N., Yamanaka K., and Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. The Journal of Biological Chemistry 276 (2001) 35552-35557
45. Wei B.Q., Mikkelsen T.S., McKinney M.K., et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. The Journal of Biological Chemistry 281 (2006) 36569-36578
46. Dembiński A., Warzecha Z., Ceranowicz P., et al. Cannabinoids in acute gastric damage and pancreatitis. Journal of Physiology and Pharmacology 57 Suppl. 5 (2006) 137-154
47. Adami M., Frati P., Bertini S., et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. British Journal of Pharmacology 135 (2002) 1598-1606
48. MacNaughton W.K., Van Sickle M.D., Keenan C.M., et al. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. American Journal of Physiology. Gastrointestinal and Liver Physiology 286 (2004) G863-G871
49. Izzo A.A., and Capasso F. Marijuana for cholera therapy. Trends in Pharmacological Sciences 27 (2006) 7-8
50. Pertwee R.G., Fernando S.R., Nash J.E., et al. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. British Journal of Pharmacology 118 (1996) 2199-2205
51. Izzo A.A., Mascolo N., Borrelli F., et al. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. British Journal of Pharmacology 124 (1998) 1363-1368
52. Storr M., Sibaev A., Marsicano G., et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. American Journal of Physiology. Gastrointestinal and Liver Physiology 286 (2004) G110-G1177
53. Mulè F., Amato A., Baldassano S., et al. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacological Research 56 (2007) 185-192
54. Abalo R., Rivera A.J., Vera G., et al. Evaluation of the effect of age on cannabinoid receptor functionality and expression in guinea-pig ileum longitudinal muscle-myenteric plexus preparations. Neuroscience Letters 383 (2005) 176-181
55. Baldassano S., Serio R., and Mule' F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. European Journal of Pharmacology 582 (2008) 132-138
56. Heinemann A., Shahbazian A., and Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 38 (1999) 1289-1297
57. Smid S.D., Bjorklund C.K., Svensson K.M., et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. European Journal of Pharmacology 575 (2007) 168-176
58. Mascolo N., Izzo A.A., Ligresti A., et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. The FASEB Journal 16 (2002) 1973-1975
59. Pinto L., Izzo A.A., Cascio M.G., et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123 (2002) 227-234
60. Izzo A.A., Capasso R., Pinto L., et al. Effect of vanilloid drugs on gastrointestinal transit in mice. British Journal of Pharmacology 132 (2001) 1411-1416
61. Yuece B., Sibaev A., Broedl U.C., et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterology and Motility 19 (2007) 744-753
62. Capasso R., Borrelli F., Aviello G., et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. British Journal of Pharmacology 154 (2008) 1001-1008
63. Capasso R., Izzo A.A., Fezza F., et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology 134 (2001) 945-950
64. Ligresti A., Bisogno T., Matias I., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125 (2003) 677-687
65. Patsos H.A., Hicks D.J., Dobson R.R., et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54 (2005) 1741-1750
66. Joseph J., Niggemann B., Zaenker K.S., et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy 53 (2004) 723-728
67. Izzo A.A., Aviello G., Petrosino S., et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine 86 (2008) 89-98
68. De Petrocellis L., Bisogno T., Ligresti A., et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundamental & Clinical Pharmacology 16 (2002) 297-302
69. D'Argenio G., Petrosino S., Gianfrani C., et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. Journal of Molecular Medicine 85 (2007) 523-530
70. Izzo A.A. The cannabinoid CB2 receptor: a good friend in the gut. Neurogastroenterology and Motility 19 (2007) 704-708
71. Kimball E.S., Schneider C.R., Wallace N.H., et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. American Journal of Physiology. Gastrointestinal and Liver Physiology 291 (2006) G364-G371
72. Storr M.A., Keenan C.M., Emmerdinger D., et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB(1) and CB (2) receptors. Journal of Molecular Medicine 86 (2008) 925-936
73. Sanson M., Bueno L., and Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterology and Motility 18 (2006) 949-956
74. Lo Verme J., Fu J., Astarita G., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Molecular Pharmacology 67 (2005) 15-19
75. Suardíaz M., Estivill-Torrús G., Goicoechea C., et al. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133 (2007) 99-110
76. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism: TEM 18 (2007) 27-37
77. Williams C.M., and Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143 (1999) 315-317
78. Jamshidi N., and Taylor D.A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. British Journal of Pharmacology 134 (2001) 1151-1154
79. Proulx K., Cota D., Castañeda T.R., et al. Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 289 (2005) R729-R737
80. Gómez R., Navarro M., Ferrer B., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. The Journal of Neuroscience 22 (2002) 9612-9617
81. Lo Verme J., Gaetani S., Fu J., et al. Regulation of food intake by oleoylethanolamide. Cellular and Molecular Life Sciences: CMLS 62 (2005) 708-716
82. Rodríguez de Fonseca F., Navarro M., Gómez R., et al. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
83. Nielsen M.J., Petersen G., Astrup A., et al. Food intake is inhibited by oral oleoylethanolamide. Journal of Lipid Research 45 (2004) 1027-1029
84. Petersen G., Sørensen C., Schmid P.C., et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochimica et biophysica acta 1761 (2006) 143-150
85. Serrano A., Del Arco I., Javier Pavón F., et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 54 (2008) 226-234
86. Oveisi F., Gaetani S., Eng K.T., et al. Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacological Research 49 (2004) 461-466
87. Fu J., Gaetani S., Oveisi F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 (2003) 90-93
88. Terrazzino S., Berto F., Dalle Carbonare M., et al. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-coenzyme A desaturase-1 mRNA expression. The FASEB Journal 18 (2004) 1580-1582
89. LoVerme J., Guzmán M., Gaetani S., et al. Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. The Journal of Biological Chemistry 281 (2006) 22815-22818
90. Fu J., Kim J., Oveisi F., et al. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 295 (2008 Apr 23) R45-R50
91. Artmann A., Petersen G., Hellgren L.I., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochimica et biophysica acta 1781 (2008) 200-212
92. Matias I., Petrosino S., Racioppi A., et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Molecular and Cellular Endocrinology 286 (2008) S66-S78
93. Cani P.D., Montoya M.L., Neyrinck A.M., et al. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. The British Journal of Nutrition 92 (2004) 757-761
94. Yang Y., Chen M., Georgeson K.E., et al. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 292 (2007) R235-R341
95. Gonçalves P., Araújo J.R., Azevedo I., et al. Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells. Pharmacology 82 (2008) 30-37
96. Després J.P., Lemieux I., and Alméras N. Contribution of CB1 blockade to the management of high-risk abdominal obesity. International Journal of Obesity (2005) 30 Suppl. 1 (2006) S44-S52
97. Côté M., Matias I., Lemieux I., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity (2005) 31 (2007) 692-699
98. Blüher M., Engeli S., Klöting N., et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-5060
99. Ravinet Trillou C., Arnone M., Delgorge C., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284 (2003) R345-R353
100. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. The Journal of Clinical Investigation 117 (2007) 13-23
101. Capasso R., and Izzo A.A. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. Journal of Neuroendocrinology 20 Suppl. 1 (2008) 39-46
102. Burdyga G., Lal S., Varro A., et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. The Journal of Neuroscience 24 (2004) 2708-2715
103. Pazos M.R., Tolón R.M., Benito C., et al. Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa. The Journal of Histochemistry and Cytochemistry 56 (2008) 511-516